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ABSTRACT Viral load measurements are an essential tool 
for the long-term clinical care of hum an immunodeficiency 
virus (HIV)-positive individuals. The gol d standards in 
viral load instrumentation, however, are still too limited 
by their size, cost, and sophisticated operation for these 
measurements to be ubiquitous in remote settings with poor 
healthcare infrastructure, including parts of the world that are 
disproportionately affected by HIV infection. The challenge 
of developing a point-of-care platform capable of making 
viral load more accessible has been frequently approached 
but no solution has yet emerged that meets the practical 
requirements of low cost, portability, and ease-of-use. In 
this paper, we perform reverse-transcription loop-mediated 
isothermal amplification (RT-LAMP) on minimally processed 
HIV-spiked whole blood samples with a microﬂ uidic and silicon 
microchip platform, and perform ﬂ uorescence measurements 
with a consumer smartphone. Our integrated assay shows 
amplification from as few as three viruses in a ~ 60 nL RT-
LAMP droplet, corresponding to a whole blood concentration 
of 670 viruses per μL of whole blood. The technology contains 
greater power in a digital RT-LAMP approach that could be 
scaled up for the determination of viral load from a ﬁ nger prick 
of blood in the clinical care of HIV-positive individuals. We 
demonstrate that all aspects of this viral load approach, from a 
drop of blood to imaging the RT-LAMP reaction, are compatible 
with lab-on-a-chip components and mobile instrumentation.
KEYWORDS human immunodeﬁ ciency virus (HIV), viral load, 
loop-mediated isothermal amplification, smartphone, point-
of-care 
1 Introduction
Human immunodeficiency virus (HIV) affects 36.9 million 
people worldwide [1]. During the course of nearly four de-
cades since the emergence of HIV on a pandemic scale, ad-
vances in antiretroviral therapy have transformed HIV infec-
tion from a death sentence into a chronic illness that can have 
little impact on life expectancy for those in whom the infec-
tion is properly managed [2]. At the population level, rates 
of new infections, mother-to-child transmission, and deaths 
from HIV-related causes are declining [2]. However, the lack 
of availability of the appropriate diagnostic technologies 
essential to informing treatment in routine HIV care is still 
among the chief barriers preventing access to the standard of 
care for millions of HIV-positive individuals worldwide, par-
ticularly in resource-limited settings.
CD4+ T lymphocyte counts and blood plasma viral load 
are the two core diagnostic measurements broadly consid-
ered essential to HIV care, as they both guide the initiation 
of therapy and indicate the efﬁ cacy of each individual’s treat-
ment regimen [3]. CD4 counts, traditionally performed by 
ﬂ ow cytometry, are increasingly available in remote settings 
due to the introduction of new portable platforms [4–7]. Viral 
load platforms, on the other hand, are well behind CD4 tech-
nologies in penetrating the developing world. Viral load in-
struments are traditionally reverse-transcription polymerase 
chain reaction (RT-PCR), nucleic acid sequence-based ampli-
ﬁ cation (NASBA), or branched DNA (bDNA) assays; although 
these can be capable of detecting fewer than ten viral RNA 
copies per mL of blood plasma, these instruments require a 
laboratory setting, extensive sample handling, and sophisti-
cated processing [6, 8–10].
One promising solution that can help address this is-
sue is loop-mediated isothermal amplification (LAMP) [11]. 
LAMP emerged in the early 2000s as an alternative to PCR 
for nucleic acid detection [12]. LAMP is attractive for point-
of-care applications because, unlike PCR, it does not require 
temperature cycling (isothermal at 60–65 °C), and because it 
is typically less sensitive than PCR to amplification inhibi-
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tors. RT-LAMP assays for HIV were ﬁ rst described soon after 
the introduction of the initial concept [13, 14], and there have 
been several reports since then regarding variations of the 
assay, including efforts toward point-of-care applications [15–
21]. Among the novel LAMP approaches applied to HIV that 
are presented in these reports are a battery-powered hand-
held microfluidic system that was demonstrated with puri-
ﬁ ed DNA [20], a SlipChip device for digital LAMP [21], and 
an electricity-free heating container that facilitates a qualita-
tive RT-LAMP assay on minimally processed whole blood [17, 
18]. To date, however, an approach capable of performing a 
quantitative RT-LAMP assay from a drop of whole blood on a 
platform compatible with a fully automated, portable device 
has not been presented.
Traditionally, it is believed that nucleic acid ampliﬁ cation 
requires complete puriﬁ cation of the RNA or DNA target in 
order to be compatible with the amplification reaction. The 
robustness of LAMP, however, has disrupted this thinking. 
Whole blood treated only with a cell lysis buffer has been 
employed by Curtis et al. for HIV LAMP in a qualitative mea-
surement in an electricity-free heating device [17]. We present 
here RT-LAMP with minimally processed lysed whole blood 
for a quantitative measurement of HIV viral load capable of 
detecting as few as three whole virus particles per ~ 60 nL 
reaction droplet.
Our approach to RT-LAMP HIV viral load measurements 
begins with a drop of whole blood. The data presented here 
demonstrate the potential of this approach to be developed 
into a fully automated mobile device that does not require 
manual processing. First, we compare and contrast the per-
formance of the RT-LAMP reaction on a standard laboratory 
thermocycler, both with purified viral RNA in water and 
with whole virus particles in whole blood that has only been 
treated with a cell lysis buffer. Next, we implement a simple 
microﬂ uidic mixing module in order to show that the whole 
blood lysis step can be performed on a chip without the 
loss of analyte or interference with the detection assay. We 
then move to a microchip platform and characterize the RT-
LAMP reaction with purified RNA and lysed whole blood 
spiked with viral RNA, imaging with both a standard ﬂ uo-
rescence microscope and a consumer smartphone without 
hardware modifications in order to compare and contrast 
standard and novel techniques. To demonstrate the robust-
ness of the assay, we show the compatibility of the on-chip 
reaction with the presence of viral RNA from the hepatitis C 
virus (HCV) and viral DNA from the hepatitis B virus (HBV), 
which do not cross-react. We then combine the microﬂ uidic 
lysis, microchip reaction platform, and smartphone imag-
ing in order to demonstrate the capability of our platform 
to quantitatively determine HIV viral load from a drop of 
blood. Finally, we discuss merits and drawbacks, as well as 
the potential for this approach to address the need for point-
of-care viral load technology.
2 Materials and methods
2.1 Samples
Whole blood. Whole venous blood samples were drawn from 
HIV-negative donors with a syringe and transferred to 4 mL 
BD Va cutainer K2 EDTA collection tubes. Tubes were stored 
at room temperature on a sample rotisserie until used for ex-
periments.
Viruses. HIV-1, strain IIIB propagated in the H9 human T ly m-
p h ocyte cell line was purchased from Advanced Biotech nolo-
gies, Inc. Virus stock was provided in puriﬁ ed form at a con-
centration of 6.7E+10 vp· mL–1 (vp is short for virus particles) in 
storage buffer containing 10 mmol·L–1 Tris, 150 mmol·L–1 NaCl, 
and 1 mmol·L–1 ethylene diamine tetraacetic acid (EDTA) at a 
pH of 7.5. Viruses used for experiments in whole particle form 
were diluted from aliquots of the stock, either in additional 
storage buffer prepared in-house or in phosphate buffered sa-
line (PBS) from Fisher Scientiﬁ c.
Viral nucleic acids. Synthetic HBV DNA (ATCC® VR-3232SD™) 
and synthetic HCV RNA (ATCC® VR-3233SD™) were pur-
chased from American Type Culture Collection (ATCC). HIV-1 
RNA was puriﬁ ed from HIV-1 IIIB whole particles using the 
PureLink® Viral RNA/DNA Mini Kit from Life Technologies. 
Two methods were used to produce dilutions of HIV-1 RNA 
for thermocycler characterization of the RT-LAMP reaction 
with puriﬁ ed RNA. In method 1, whole virus particles were 
diluted in PBS and each dilution was separately puriﬁ ed in 
the PureLink® kit. In method 2, 10 μL of 6.7E+10 vp· mL–1 
was added to 190 μL PBS to meet kit speciﬁ cations, and was 
then puriﬁ ed and eluted in 150 μL RNase-free water for a ﬁ -
nal concentration of 4.47E+9 vp· mL–1 (or 8.93E+9 RNA copies 
per mL). This puriﬁ ed RNA was then aliquoted and stored at 
–80 °C until use.
Microchip RT-LAMP experiments were performed with 
this viral RNA, with the exception of the integrated experi-
ment. The experiments performed with puriﬁ ed RNA in wa-
ter were done because puriﬁ ed RNA is the standard analyte 
in reverse-transcription nucleic acid ampliﬁ cation assays and 
these experiments serve as a basis for comparison to lysed 
whole blood. Whole virus particles are the ideal analyte in 
whole blood; however, the preliminary microchip experi-
ments were performed with viral RNA spiked in whole blood 
for biosafety reasons while the technique was being devel-
oped. Preliminary “macroscale” amplification experiments 
with whole blood in a thermocycler (not on a microchip) did 
include whole virus particles because the technique was 
compatible with biosafety practices. To perform the ﬁ nal, in-
tegrated on-chip experiment, an apparatus was constructed 
in a biosafety cabinet in order to accommodate microchip 
experiments with whole virus particles.
Blood cell lysis. The whole blood lysis buffer was based on 
the work by Curtis et al. [17] and contained 2.5 mmol· L–1 
KHCO3, 37.5 mmol· L–1 NH4Cl, and 0.025 mmol· L–1 EDTA. A 
1:4 ratio of blood to lysis buffer was used for all lysed blood 
experiments. In preliminary experiments, blood and lysis 
buffer were metered and mixed with a manual pipettor, 
while the ﬁ nal integrated experiment and the preliminary 
experiment to characterize microfluidic mixing employed 
on-chip lysis in a microfluidic channel. For microfluidic 
mixing, the ratio of volumes mixed was ﬁ xed to 1 : 4 by set-
ting relative flow rates from two syringe pumps driving 
each component.
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2.2 RT-LAMP
Reaction components. The RT-LAMP assay was adapted 
from the work by Curtis et al. [17]. Reaction concentra-
tions of buffers were 1× isothermal amplification buffer, 
1.4 mmol· L–1 deoxy-ribonucleoside triphosphates (dNTPs), 
and 10 mmol· L–1 MgSO4 from New England Biolabs, and 0.4 
mol· L–1 betaine from Sigma-Aldri ch. In some cases, where 
indicated, 0.8 mol· L–1 betaine was used. These reaction buffer 
components were prepared in appropriate ratios in bulk and 
stored at –20 °C between experiments. Enzymes and DNA 
intercalating dye were added separately to this buffer mix for 
a complete master mix that was freshly prepared for each ex-
periment. The RT-LAMP enzymes used in the reaction were 
0.64 U· μL–1 Bst 2.0 DNA polymerase and 0.08 U· μL– 1 AMV re-
verse transcriptase fro m New Engl and Biolabs. 1× EvaGreen 
from Biotium, a double-stranded DNA (dsDNA) intercalating 
dye, was included in the reaction for the detection of reaction 
products.
Primers. Six LAMP primers were based on the study by Cur-
tis et al. [17], including a six-primer set containing 0.2 μmol· L–1 
each of F3 (5’-AGTTCCCTTAGATAAAGACTT-3’) and B3 
(5’-CCTACATACAAATCATCCATGT-3’) primers, 1.6 μmol· L–1 
each of forward inner primer (FIP) (5’-GTGGAAGCACATT 
GTACTGATATCTTTTTGGAAGTATACTGCAT-TTACCAT-3’) 
and backward inner primer (BIP) (5’-GGAAAGGATCAC 
CAGCAATATTCCTCTGGATTTTGTTTTCTAAAAGGC-3’), 
and 0.8 μmol· L–1 each of LoopF (5’-GGTGTCTCATTGTT 
TATACTA-3’) and LoopB (5’-GCATGACA-AAAATCTTA
GA-3’) primers.
Negative controls. All amplification experiments, whether 
in the thermocycler or on the microchip, included negative 
controls that consisted either of water without RNA or lysed 
blood without viruses/viral RNA, according to the nature of 
the positive samples being tested. Ampliﬁ cation of the nega-
tive control within the reaction timeframe was considered to 
be an indication of a contaminated test. Fluorescence curves 
are not presented for these negative controls, although they 
were included in every experiment.
Reaction platforms. RT-LAMP reactions were performed on 
two different platforms at various stages of this study. For the 
purpose of establishing the RT-LAMP reaction and compar-
ing and contrasting puriﬁ ed RNA in water with lysed whole 
blood, standard 25 μL reactions were performed in 0.2 mL 
reaction tubes in an Eppendorf Mastercycler® ep realplex 
Real-Time PCR System. The thermocycler was also used for 
RT-LAMP reactions characterizing the microfluidic mixing 
module in order to eliminate possible noise introduced by the 
microchip system.
To develop the microchip ampliﬁ cation, several microchip 
experiments were performed, beginning with RNA in water 
and RNA-spiked lysed whole blood (RNA was used for bio-
safety reasons in these preliminary experiments as explained 
above). Each individual droplet (reaction) on the microchip 
contained approximately 60 nL and the entire microchip was 
placed in a copper bowl, as described below, and heated on 
an INSTEC STC200 heating stage. Imaging was initiall y per-
formed with a Nikon Eclipse FN1 ﬂ uorescence microscope in 
order to employ a standard imaging method. Later, a Sam-
sung Galaxy Note 4 smartphone was introduced. Both the 
fluorescence microscope and the smartphone were used in 
order to compare the imaging capabilities of the smartphone 
with those of standard laboratory imaging equipment. The 
reactions were initially incubated at 60 °C in the commercial 
thermocycler and later at 65 °C for the on-chip experiments. 
Fluorescence measurements were performed every 60 s with 
the thermocycler and ﬂ uorescence microscope, but increased 
to every 30 s with the smartphone platform.
Data are presented in this paper for microchip reactions 
with puriﬁ ed RNA in water imaged with a microscope and 
RNA-spiked lysed whole blood imaged with a smartphone. 
The intermediate experiment, RNA-spiked lysed whole blood 
reactions imaged with a microscope, is provided in the Sup-
plementary Information.
2.3 Microﬂ uidic lysis module
Fabrication. The microﬂ uidic lysis module is based on an ear-
lier design that was reported previously [22]. The polydimeth-
ylsiloxane (PDMS)-on-glass microfluidic channel was made 
from an SU-8 master mold fabricated using standard clean-
room photolithography techniques. Uncured PDMS was 
poured over the SU-8 master, degassed in a desiccator, and 
cured on a hot plate at 60 °C. Holes for tubing connections 
were punched into the PDMS with a 1.5 mm biopsy punch, 
prior to solvent degreasing and the oxygen plasma surface 
activation of both the PDMS and a glass microscope slide in a 
Diener PICO plasma system. Activated surfaces of the PDMS 
and glass were brought into contact following surface activa-
tion and heated at 60–70 °C on a hot plate, producing covalent 
bonds between the two pieces.
Fluidic apparatus. The microfluidic lysis experiments in-
volving whole HIV particles were performed with a fluidic 
apparatus that interfaced with the PDMS microfluidic chips 
and consisted of syringe pumps and high-performance liquid 
chromatography (HPLC) valves built within a biosafety cabi-
net. Biosafety level 2+ protocols were followed.
2.4 On-ch ip RT-LAMP
Chip fabrication. Microchip RT-LAMP experiments emplo-
yed a microfabricated silicon substrate [23]. Brieﬂ y, a silicon 
wafer was thermally oxidized to create a silicon oxide layer 
of ~ 150 nm. The oxide was then patterned with photoli-
thography and a hydrofluoric acid etch step, exposing the 
silicon where the wells would be etched. The wafer was then 
immersed in a heated tetramethylammonium hydroxide 
(TMAH) bath for 18 h in order to anisotropically etch the sili-
con, creating inverted square pyramids that would later be 
used as reaction wells. An approximation of the dimensions 
of the inverted square pyramids is provided in the Supple-
mentary Information.
Chip preparation. Chips for all microchip RT-LAMP experi-
ments were prepared in the following manner: First, the mi-
crochip was cleaned in a piranha solution containing 1:3 30% 
hydrogen peroxide and sulfuric acid for 10 min and then it 
was rinsed in deionized water. Each chip was then degreased 
with acetone, methanol, and isopropanol and dried by blow-
ing with nitrogen gas. To produce a hydrophobic surface 
327
Medical Instrumentation—Article Research
www.engineering.org.cn  Volume 1 · Issue 3 · September 2015  Engineering
to promote stability of droplets, the chip was rinsed with 
Sigmacote® from Sigma-Aldrich by pipetting the solution 
repeatedly over the surface of the chip. The chip was then 
rinsed brieﬂ y with isopropanol, dried by blowing with nitro-
gen gas, and placed in a copper bowl.
Microinjection. A Narishige IM-300 Microinjector with Ep-
pendorf VacuTip microinjection holding capillary (15 μm in 
inner diameter, 100 μm in outer diameter) was used both to 
spot primers and to place reaction droplets. A 20 ms injection 
pulse was used, resulting in a droplet of approximately 60 
nL. The microinjection procedure was performed after chip 
cleaning and preparation as follows: LAMP DNA primers 
in Tris-EDTA (TE) buffer were diluted in water to the final 
reaction concentration. Droplets were placed in all 36 wells 
of the microchip array using the microinjection system and 
a 3D micromanipulator (MCL-D331) from World Precision 
Systems. The process was visualized with a Leica MZFLIII 
microscope. Droplets containing primers were allowed to dry 
completely, leaving dehydrated DNA LAMP primers in the 
reaction wells. Following visual conﬁ rmation that all droplets 
had dehydrated, the chip was submerged in heavy mineral oil 
(Fisher) and placed in a desiccator to remove air bubbles. The 
primary function of the mineral oil was to protect the reaction 
droplets from evaporation during heating at 65 °C.
During degassing, the primer-less RT-LAMP reaction was 
prepared and transferred to the microinjection capillary. Re-
action droplets were then placed in each well by lightly con-
tacting the bottom of each reaction well, injecting a droplet of 
approximately 60 nL, and lifting the capillary out of the oil. 
The chip containing all 36 droplets submerged in oil in the 
copper bowl was then transferred to the heating stage and 
imaging apparatus (ﬂ uorescence microscope or smartphone 
apparatus).
Primer spotting and reaction droplet placement for the in-
tegrated experiment were performed in the same manner but 
within a biosafety cabinet under a Leica EZ4D microscope 
with a built-in camera providing a live video feed to a per-
sonal computer (PC).
2.5 Fluorescence microscopy
Fluorescence microscopy images were captured with a Nikon 
Eclipse FN1 ﬂ uorescence microscope with a 2× objective and 
a Nikon 96311 B-2E/C FITC ﬂ uorescence ﬁ lter. NIS Elements 
software was used to capture fluorescence images for RT-
LAMP reactions containing puriﬁ ed RNA in water with 6.3× 
gain and 1 s exposure time. Additional measurements (pre-
sented in the Supplementary Information) with lysed whole 
blood spiked with viral RNA imaged with the microscope 
required 8× gain and a 2 s exposure time to compensate for 
decreased overall ﬂ uorescence intensity.
2.6 Smartphone imaging
Apparatus. A Samsung Galaxy Note 4 smartphone was pur-
chased for the imaging of the RT-LAMP reaction on the mi-
crochip substrate. The smartphone hardware was not modi-
ﬁ ed from its factory conditions. A Thorlabs 530 nm Longpass 
Colored Glass Filter was placed between the camera and the 
chip to isolate the ﬂ uorophore emission wavelengths. A 3D-
printed cradle (Figure 1) was designed to position the smart-
phone horizontally with the camera directly above the mi-
crochip. A mounting cylinder was also 3D printed to hold an 
Opto Diode Corp high-output blue light-emitting diode (LED) 
and a Thorlabs Shortpass Filter with a 500 nm cut-off wave-
length, which fit within the cradle and illuminated the mi-
crochip from an angle. The LED was powered with 3 V from 
an Agilent E364xA DC power supply with an automated on/
off function controlled with a MATLAB script. It was also de-
termined that the blue LED could be adequately powered by 
a standard 3 V lithium coin battery, but the DC power supply 
was used for the purpose of PC control.
Software. Due to biosafety considerations, the entire smart-
phone imaging apparatus was placed inside a biosafety 
cabinet when performing integrated measurements. For this 
reason, remote control of the imaging function was desired, 
so the Android application IP Webcam [24] was downloaded 
from the Google Play store and installed on the smartphone. 
This application transmits a live image over the network, 
which can be viewed in real time in a web browser. The 
browser interface allowed for control of the smartphone 
camera’s focus, exposure, and gain. Imaging of the RT-LAMP 
reaction was performed with the following parameters set in 
the IP Webcam web browser interface: 8× zoom, 99% stream 
Figure 1. The RT-LAMP substrate and smartphone apparatus. (a) Image 
of 1 cm × 1 cm silicon microchip substrate sitting on a Samsung smartphone. 
(b) Scanning electron microscopy cross-section of 160 µm-deep reaction wells. 
(c) Schematic of microchip and heating stage in fluorescence microscope 
apparatus, including: (i) heating stage, (ii) copper base containing mineral 
oil, and (iii) fluorescence microscope objective. (d) Expanded diagram of 
smartphone LAMP apparatus, including: (i) heating stage, (ii) copper base 
containing mineral oil, (iii) wavelength filters placed in front of the LED and 
smartphone camera, (iv) blue LED light source, and (v) smartphone. (d-inset) 
Image of apparatus assembled in biosafety cabinet.
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quality, exposure compensation of 4, 
and “night vision” function with a gain 
of 10× and exposure 10.
A MATLAB script was written to au-
tomate the image-capture process. The 
script was initialized simultaneously 
with the activation of the heating stage. 
The MATLAB script imaged the reac-
tion in the following sequence: Switch 
on blue LED, delay 3 s; capture image 
from IP Webcam web browser interface, 
delay 2 s; and finally switch off blue 
LED. This process was repeated every 
30 s while each reaction was imaged.
2.7 Data analysis
Image analysis. Images recorded with 
fluorescence microscopy or the smart-
phone imaging apparatus were saved as 
TIFF (microscope) or JPEG (smartphone) 
files and fluorescence intensity was 
analyzed. For this analysis, the physi-
cal location of each droplet was identi-
fied manually in a MATLAB script by 
importing and displaying the image 
in a MATLAB ﬁ gure and adjusting the 
position of square boxes outlining each 
droplet. Grayscale TIFF images were 
imported as a matrix of 16-bit unsigned 
integers (range 0–65 535) representing 
each pixel in the image. Grayscale JPEG 
images were imported as an array of 
8-bit unsigned integers (range 0–255) 
representing each pixel in the image.
Following manual identification of 
droplet positions, a MATLAB script 
automated the analysis of each droplet 
by averaging the numerical value of 
all pixels within the region defined by 
the box outlining each droplet. Abso-
lute numerical values are a function of 
the range of integer values (8-bit or 16-
bit), as well as the exposure time and 
gain of the camera, ambient light in the 
laboratory, and other factors. For this 
reason, the baseline is subtracted from 
each measurement as described below, 
and fluorescence measurements in this 
paper are presented in arbitrary units 
(AU).
Threshold time analysis. Threshold time 
was determined from raw ﬂ uorescence 
data on all platforms. First, the baseline 
was removed by subtracting an early 
fluorescence measurement from all 
subsequent measurements. For all ther-
mocycler measurements and the micro-
scope measurements with puriﬁ ed RNA 
in water, this was the ﬁ rst ﬂ uorescence 
value or image recorded. For smartphone measurements, the auto ﬂ uorescence of 
whole blood at room temperature was observed to decrease quickly upon initial 
heating of the chip. Thus, the baseline was deﬁ ned to be 90 s after initialization of 
the heating, or the third image recorded by the smartphone.
The threshold time for each individual reaction was approximated from baseline-
subtracted ﬂ uorescence curves by determining the measurement n at which the sig-
nal exceeded 20% of the maximum ﬂ uorescence value it achieved during the course 
of the entire measurement. After determining n, a linear ﬁ t was determined by the 
ﬂ uorescence values In and In–1 in the form I(x) = mx + b and the threshold time Tt = (0.2 
× Imax – b)/m was determined.
3 Results
3.1 Characterization of RT-LAMP in a benchtop thermocycler
Purified viral RNA in water. The first experiment, presented in Figure 2(a) and 
(b), was performed in order to characterize the RT-LAMP reaction with puriﬁ ed 
analyte in a standard thermocycler apparatus. HIV-1 IIIB RNA was puriﬁ ed by two 
different methods as described in Section 2.1. RT-LAMP fluorescence curves for 
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Figure 2. RT-LAMP performed in a standard benchtop thermocycler. (a) Raw ﬂ uorescence data for RT-
LAMP of viral RNA diluted and puriﬁ ed from dilutions of whole HIV-1 IIIB virus particles (RNA puriﬁ cation 
method 1). (b) Threshold time curves determined by calculating the time at which fluorescence curves 
exceed 20% of their maximum value. Data are included for both methods of producing puriﬁ ed viral RNA. 
(c) Fluorescence curves from six replicates of each condition comparing RT-LAMP in virus-spiked whole 
blood versus puriﬁ ed RNA. All reactions contained the equivalent of 9380 virus particles. (d) Comparisons 
of threshold time and overall fluorescence intensity for both conditions. (e) Fluorescence curves and 
(f) standard curve for RT-LAMP with HIV-1 IIIB whole viruses spiked in whole blood. The 9.4 vp ·RXN–1 
sample is not included in (f) due to inconsistent ampliﬁ cation of all replicates. RXN is short for reaction.
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the first method are shown in Figure 
2(a), and the calculated threshold time 
versus the average number of viruses 
in each reaction is shown in Figure 2(b). 
Linear ﬁ ts to threshold time versus log 
of viruses showed a difference in slope 
of less than 1.3% but a vertical offset of 
more than 4 min in the y-intercept.
Comparison with lysed whole blood. 
The next experiment compared the 
threshold time and fluorescence inten-
sity of RT-LAMP containing 9380 whole 
virus particles of HIV-1 IIIB in lysed 
blood to the corresponding amount of 
puriﬁ ed HIV-1 RNA in water as an ini-
tial test of the feasibility of RT-LAMP in 
lysed whole blood. Figure 2(c) shows ﬂ u-
orescence measurements and Figure 2(d) 
provides bar charts comparing threshold 
time and maximum ﬂ uorescence value. 
Six replicates were performed of each 
of the two conditions, and the average 
threshold time in lysed blood varied by 
less than 2.3% compared to RNA in wa-
ter, and gave a P of 0.0755 in a standard 
two-sample t test. The maximum overall 
ﬂ uorescence intensity (determined from 
raw ﬂ uorescence measurements with the 
baseline subtracted) showed a decrease 
in ﬂ uorescence signal of 88.93% in lysed 
whole blood compared to puriﬁ ed RNA 
in water.
Standard curve in lysed whole blood. 
An experiment with whole virus par-
ticles at a range of concentrations was 
then performed in order to characterize 
the RT-LAMP reaction on an ideal plat-
form but with a minimally processed 
sample. Figure 2(e) (ﬂ uorescence inten-
sity curves) and (f) (threshold time ver-
sus virus number) show that even with 
a ten-fold reduced overall fluore scence 
inten sity, amplification curves could 
still be observed and threshold times 
analyzed. A linear fit to the threshold 
time versus the log of virus number 
gives a slope comparable to purified 
RNA curves (10.3% difference com-
pared to method 1 and 9.1% difference 
compared to method 2 in Figure 2(b)). 
Due to inconsistent amplification of 
all replicates, the 9.4 vp·RXN–1 sample 
is not included in the threshold time 
curve. Further characterization of the 
lysed whole blood RT-LAMP reaction 
was performed by examining variations 
on the ratio of blood sample to lysis buf-
fer. Results are provided in the Supple-
mentary Information.
3.2 Microﬂ uidic blood lysis module
On-chip lysis in a microﬂ uidic channel, shown in Figure 3(a), was independently 
characterized in order to determine the potential for automated sample handling 
and to characterize any impact of the microﬂ uidic mixing on the overall method. 
Whole blood samples spiked with three different concentrations of HIV-1 IIIB were 
each mixed with lysis buffer in the polydimethylsiloxane (PDMS) mixing chip 
driven by the ﬂ uidics apparatus in a biosafety cabinet, as described in Section 2.3. 
Output from the microﬂ uidic chip was collected on three separate instances from 
each sample and analyzed separately with RT-LAMP in a thermocycler. Triplicate 
RT-LAMP reactions were performed for each of the three collections, resulting in 
nine total RT-LAMP reactions for each virus concentration investigated. As a con-
trol, the same spiked blood samples were added to lysis buffer, mixed with a pi-
pette, and analyzed with RT-LAMP in triplicate (i.e., three control reactions in total 
for each virus concentration). Figure 3(b) shows the results. Mean threshold times 
differed from those of the manually-pipetted control by 0.85%, 3.88%, and 8.21% 
for post-lysis virus concentrations of 1349 vp· μL–1, 135 vp· μL–1, and 13 vp· μL–1, 
respectively.
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3.3 On-chip RT-LAMP
Next, the RT-LAMP reaction was demonstrated on the microchip. This included 
experiments with puriﬁ ed RNA in water, shown in Figure 4(a) and (b), and RNA 
in lysed whole blood (presented in the Supplementary Information), imaged with 
a fluorescence microscope before the introduction of the smartphone, as shown 
in Figure 4(c) and (d). This sequence of experiments was performed in order to es-
tablish a basis for comparison and to limit the introduction of new variables and 
sources of noise in each step in the progression of the experiments. All on-chip RT-
LAMP measurements were prepared as described in Section 2.4 with DNA LAMP 
primers pre-spotted and dehydrated on the chip prior to oil immersion, degassing, 
and reaction droplet placement.
Puriﬁ ed RNA in water was ﬁ rst characterized on the chip. Figure 4(a) displays 
fluorescence curves measured with a fluorescence microscope, while Figure 4(b) 
shows the threshold time analysis. In this measurement, data from two droplets 
were removed due to outlying behavior believed to be due to contamination with 
inhibitors or experimenter error. This includes one of six reactions in each of the 
75 vp· RXN–1 and 7.5E+2 vp· RXN–1 samples. Only two of six 7.5 vp· RXN–1 samples 
ampliﬁ ed, and as a result, threshold times for this sample were omitted from the 
curve in Figure 4(b). In Figure 4(c)–(f), lysed whole blood spiked with viral RNA 
was imaged with the smartphone apparatus as described in the Section 2.6. Whole 
Figure 3. Microﬂ uidic lysis of whole blood samples. (a) Diagram of the microﬂ uidic device with bright-
ﬁ eld microscopy at various points in the channel with their approximate locations indicated. (b) A comparison 
of threshold time at three virus concentrations for chip-lysed versus pipette-lysed samples containing whole 
virus particles. These data verify that the microﬂ uidic lysis method does not result in signiﬁ cant differences in 
signal compared to the manual method.
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virus particles were not used in this measurement, as the apparatus had not yet 
been converted to be contained within a biosafety cabinet. Figure 4(c) shows 
ﬂ uorescence curves gleaned from the smartphone images, Figure 4(d) shows the 
threshold time analysis, and Figure 4(e) shows examples of the smartphone ﬂ uo-
rescence images every minute for minutes 7–11. The 11 vp· RXN–1 (green) and 1.1 
vp· RXN–1 (blue) samples are omitted from the threshold time curve because of in-
sufﬁ cient ampliﬁ cation before 30 min.
Figure 4(f) shows an endpoint measurement obtained following termination 
of the real-time monitoring at 30 min. Four additional droplets (three of the 11 
vp· RXN–1 samples and one 1.1 vp· RXN–1 sample) in the array had reacted before 
the image in Figure 4(f)-1) was captured with the ﬂ uorescence microscope. Figure 
4(f)-2) is an additional smartphone image captured shortly after the microscopy 
image was obtained. Figure 4(f)-3) is 
identical to Figure 4(f)-2) with an ad-
ditional color-coded overlay that is 
consistent with the color-concentration 
convention used throughout this pa-
per. The sixth column on the far right 
is a negative control containing a blood 
sample and reaction mix without viral 
RNA.
Finally, Figure 4(f)-4) is a color map 
rendering of Figure 4(f)-2) that was pro-
duced in MATLAB as an example of the 
image analysis process.
3.4 Compatibility with other viral nucleic 
acids
Due to the common occurrence of co-
infections of HIV and viral hepatitis 
(HBV and/or HCV), we sought to dem-
onstrate the compatibility of this on-
chip RT-LAMP assay with such cases. 
Because whole virus particles were not 
available to us for hepatitis viruses, 
synthetic viral genomes of DNA (HBV) 
and RNA (HCV) were obtained and 
tested. Since limited quantities of the 
synthetic viral genomes were available 
to us, this experiment was performed 
in water and not lysed whole blood in 
order to avoid the ten-fold dilution of 
nucleic acids that would result from 
spiking lysed blood with viral nucleic 
acids and to perform the test at the 
highest concentration of viral nucleic 
acids possible.
Figure 5(a) shows fluorescence data 
obtained with the fluorescence micro-
scope measurement system for the on-
chip RT-LAMP of three samples: HIV 
both with and without hepatitis virus 
nucleic acids, and hepatitis virus nucle-
ic acids without HIV. All 24 of the drop-
lets containing HIV RNA successfully 
amplified (twelve with hepatitis virus 
nucleic acid, twelve without), regardless 
of the presence of other nucleic acids. 
The twelve HIV-negative droplets, all 
containing hepatitis virus nucleic acids, 
did not amplify.
Figure 5(b) shows a comparison of 
threshold time between the two HIV 
RNA-containing conditions. The aver-
age threshold time for HIV-positive 
droplets that contained hepatitis nucleic 
acid differed from the droplets that did 
not by 8.90%. A standard t test compar-
ing the two gives a P of 1.8718E–6.
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Figure 4. On-chip RT-LAMP for HIV-1 IIIB. (a) Baseline-subtracted ﬂ uorescence intensity and (b) threshold 
time versus virus concentration for purified RNA in water on the micro-well substrate imaged with a 
ﬂ uorescence microscope. (c) Baseline-subtracted ﬂ uorescence intensity and (d) threshold time versus virus 
concentration for RNA-spiked lysed whole blood on the micro-well substrate imaged with the smartphone 
camera. (e) Fluorescence images captured by the smartphone showing the amplification of four RNA 
concentrations. (f) Endpoint measurements of the same chip in (c)–(e) showing: 1) ﬂ uorescence microscopy, 
2) the smartphone image, 3) color overlay indicating concentrations (the gray bar indicates negative 
controls), and 4) a ﬂ uorescence intensity colormap created in MATLAB in the process for quantifying the 
intensity in images.
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3.5 Integrated experiments
Integrated experiments were designed to demonstrate the 
full capacity of this approach for a sample-to-answer solution 
to point-of-care HIV viral load quantiﬁ cation. Figure 6(a) de-
picts the complete ﬂ ow of the process. These experiments dif-
fered from the other measurements presented in this paper 
in that whole blood samples were spiked with whole HIV-1 
IIIB virus particles (not viral RNA) at a range of concentra-
tions and each individual sample was analyzed on a separate 
chip. Of the 36 wells on the microchip array, 6 were used for 
negative controls and up to 30 were used to test the sample.
Five samples were tested (named A–E), containing approxi-
mately 32 000, 3200, 320, 32, and 3.2 whole virus particles per 
reaction, respectively. Since each reaction droplet contains 
approximately 4.8 nL of whole blood, this corresponds to 
viremias in the range of 6.7 × 105–6.7 × 109 viruses per mL 
of blood, or 1.3 × 106–1.3 × 1010 RNA copies per mL of blood 
plasma (assuming 45% haematocrit).
Due to biosafety considerations, the entire process was 
adapted, as described previously, to be contained within a 
biosafety cabinet. This adaptation introduced challenges to 
the droplet placement, which was performed with a motor-
ized micromanipulator controlled with a joystick and guided 
by a video feed from a small tabletop microscope. Decreased 
control over droplet placement led to a decreased success rate 
in droplet placement. As a result, not all of the 30 wells desig-
nated for a virus-positive reaction droplet were used in every 
measurement. The numbers of successfully placed droplets 
for samples A through E were as follows: 29, 28, 30, 22, and 22.
Figure 6(b) shows the ﬂ uorescence curves, measured with 
the smartphone system, for all droplets that ampliﬁ ed within 
8
6
4
2
0
10 20
Time (min)
(a) (b)
HIV+
HBV–
HCV–
HIV+
HBV+
HCV+
30
10
8
6
4
4
0
Th
re
sh
ol
d 
tim
e 
(m
in
)
Fl
uo
re
sc
en
ce
 in
te
ns
ity
(×
10
3  a
.u
.)
HIV+
HBV+
HCV+
HIV+
HBV–
HCV–
HIV–
HBV+
HCV+
Figure 5. A demonstration of compatibility with common co-infections. 
The HIV-1 on-chip RT-LAMP reaction was tested in the presence of HBV and 
HCV nucleic acids at concentrations equivalent to 1.6 × 103 of each virus per 60 
nL reaction. LAMP primers for HIV-1 detection were dehydrated in each well of 
the microchip array and puriﬁ ed nucleic acids in water were prepared in various 
combinations with a primer-less RT-LAMP master mix. The chip was immersed 
in mineral oil and placed under a ﬂ uorescence microscope on a heating stage at 
65 °C. (a) Fluorescence measurements from the ﬂ uorescence microscopy chip 
of three combinations: HIV+/HBV–/HCV–, HIV+/HBV+/HCV+, and HIV–/HBV+/
HCV+. (b) A bar chart comparing threshold time for HIV RNA-positive samples 
with and without hepatitis virus nucleic acid present.
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Figure 6. Sample-to-answer RT-LAMP detection of HIV-1 IIIB in lysed whole blood. (a) A schematic of the integrated process: 1) Whole blood spiked with HIV-1 
IIIB was infused into a microﬂ uidic apparatus; 2) 10 µL of sample was metered based on the volume of the holding coil; 3) the sample was ﬂ owed into a microﬂ uidic 
mixing module at 10 µL·min–1 with cell lysis buffer at 40 µL·min–1; 4) output from the mixing module was added to the RT-LAMP master mix without primers; 5) a 
lysed sample with master mix was microinjected onto the microwell substrate prepared with dehydrated primers; 6) the chip was heated to 65 °C in a copper base 
with a heating stage and the RT-LAMP reaction was monitored by recording a ﬂ uorescent image every 30 s using a smartphone. (b) Real-time ﬂ uorescence curves 
as measured by smartphone imaging system. (c) Threshold time values determined by the time at which baseline-subtracted ﬂ uorescence intensity exceeded 20% 
of its maximum value. (d) Ampliﬁ cation efﬁ ciency, deﬁ ned as the fraction of droplets that ampliﬁ ed in the array for each tested concentration.
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30 min. Figure 6(c) shows the threshold time versus the virus 
number. The slope of the fit to threshold time versus virus 
number is –1.9993, which differs in magnitude by 57.6% com-
pared to on-chip RNA in lysed whole blood, by 34.9% com-
pared to on-chip RNA in water, by 18.5% compared to whole 
virus particles in whole blood in the thermocycler, and by 
25.9% compared to puriﬁ ed RNA in water (method 2 in Sec-
tion 2.1) analyzed in the thermocycler. A t test was performed 
to compare the threshold time and significance was deter-
mined by a P < 0.05. 
In Figure 6(d), we consider a new metric—amplification 
efﬁ ciency—and observe a trend between virus number and 
the fraction of droplets that ampliﬁ  ed. A framework for un-
derstanding this phenomenon in the context of digital LAMP 
measurements is described in the Supplementary Informa-
tion.
4 Discussion
4.1 Characterization of RT-LAMP in a benchtop thermocycler
Purified viral RNA in water. In the initial thermocycler ch ar-
a cterization of this RT-LAMP reaction, we presented a com-
parison of two methods (see Section 2.1) of viral RNA puriﬁ -
cation in order to ① establish a baseline for a “clean” reaction 
signal, and ② highlight possible factors that may contribute 
to variations in RT-LAMP results in subsequent analyses.
While the two independent experiments measuring puri-
ﬁ ed RNA in water differed in the manner in which dilutions 
were performed (before RNA purification in method 1 and 
after RNA puriﬁ cation in method 2), they also differed in be-
taine content (0.8 mol· L–1 in method 1, 0.4 mol· L–1 in method 
2). After the initial measurements, betaine concentration was 
decreased in order to allow for a larger fraction of the reac-
tion volume to consist of sample. One initial hypothesis was 
that betaine, which contains a cation and reduces secondary-
structure formation in DNA, may explain the difference in 
the two standard curves. However, a careful comparison 
was performed in which RNA at various low concentrations 
was added to a common master mix containing 0.4 mol· L–1 
betaine and, in half of the reactions, additional betaine was 
added to achieve a concentration of 0.8 mol· L–1. The results of 
this control experiment (see the Supplementary Information) 
indicated no difference in the threshold time nor in the am-
pliﬁ cation efﬁ ciency at lower concentrations. Therefore, other 
factors likely explain the vertical offset in the puriﬁ ed RNA 
experiment in the thermocycler.
We suspect that these factors may include variations in 
enzyme concentration due to inherent variation in the pipet-
ting process when preparing master mixes, a time-related 
decrease in enzyme activity (the two experiments were per-
formed several weeks apart and enzyme activity may have 
decreased with freeze-thaw cycles of the reagent), or varia-
tions in ambient temperature and other factors. Additionally, 
degradation of RNA over time during storage may have de-
creased the yield of the samples used in method 2, and varia-
tions due to manual pipetting may contribute to discrepan-
cies between the actual RNA concentrations gleaned from 
the two independent puriﬁ cation procedures.
While these factors are important to consider, we chose at 
this time to acknowledge their potential effects and the need 
to minimize variation and decided to establish rigorous con-
trols in future experimental or manufacturing processes. Vi-
ral RNA stability or yield from the RNA puriﬁ cation process 
would not affect the results of experiments using whole virus 
particles. Subsequent analysis involving puriﬁ ed viral RNA 
or viral RNA spiked in whole blood employed RNA from a 
third, “fresh” puriﬁ cation identical in protocol to puriﬁ cation 
method 2. The puriﬁ ed RNA from this process was aliquoted 
and frozen at –80 °C and thawed only immediately before 
use in an experiment in order to minimize degradation of the 
sample between experiments.
Comparison with lysed whole blood. To our knowledge, a 
quantitative RT-LAMP measurement of HIV concentration in 
whole blood processed only by mixing with a cell lysis buf-
fer has not been described previously in literature. The ther-
mocycler results with whole virus particles spiked in whole 
blood and mixed with cell lysis buffer suggest the possibility 
of quantifying virus concentration simply based on reaction 
kinetics.
The decrease in overall ﬂ uorescence intensity indicates that 
there are fluorescence-quenching components in the lysed 
whole blood sample. However, because the threshold time is 
identical when comparing purified RNA and whole blood, 
we can conclude that whole blood does not affect the ampliﬁ -
cation efﬁ ciency. This is a very promising development, given 
that a major challenge to most point-of-care diagnostics is the 
process of isolating analyte from complex biological samples 
in the absence of controlled environments, skilled techni-
cians, or laboratory instruments [25]. In this case, blood cell 
lysis is an extremely simple processing step compared to the 
more complicated techniques described in the literature [6].
4.2 Microﬂ uidic blood lysis module
One goal of this paper is to demonstrate the potential for a 
fully automated RT-LAMP viral load test from a drop (i.e., a 
ﬁ nger prick) of whole blood. Such a test requires complete on-
chip sample processing from that whole blood drop, which 
has traditionally been a major barrier for many point-of-care 
diagnostics approaches. Despite the popularity of PDMS pro-
totyping in this field, many microfluidic and lab-on-a-chip 
techniques suffer from the ability to translate PDMS devices 
to commercially viable forms that are compatible with injec-
tion molding and other mass-manufacturing techniques [26]. 
The converse is also true: That designs compatible with man-
ufacturing may be difﬁ cult to prototype in PDMS when some 
properties (e.g., surface-fluid contact angle) are not compa-
rable. Here we demonstrate valve-assisted sample metering 
and microfluidic mixing resembling a method that we are 
aware is employed in commercial-grade platforms for blood-
sample handling.
Volumetric metering begins with a drop of blood of un-
specified size from which 10 μL is precisely metered in a 
holding coil with an inner diameter of 203.2 μm, reminiscent 
of commercial microﬂ uidic cartridges that employ volumet-
ric metering. Viable methods have also been employed for 
ﬂ uid mixing in commercial microﬂ uidic designs, making our 
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simple serpentine channel prototyped in PDMS a reasonable 
design [27].
Data in Figure 3(b) demonstrate that this simple approach 
of volumetric metering with the serpentine-channel mixing 
of blood with lysis buffer is compatible with the downstream 
RT-LAMP analysis. The results from three separate collec-
tions show that the method produces an accurate mixing 
ratio, and that the on-chip mixing is at least as consistent as 
manual pipetting.
4.3 On-chip RT-LAMP
Purified RNA with fluorescence microscope imaging. It is 
unclear what absolute conclusions can be gleaned from a 
comparison of the ﬁ t to the threshold time versus the log of 
virus number in Figures 2(b) and 4(b). The slope of the ﬁ t is 
smaller in magnitude for the on-chip measurement, suggest-
ing that there may be some chip-related factors leading to a 
decrease in sensitivity for the quantiﬁ cation of virus number 
by threshold time analysis. This observation prompted in-
creasing the frequency of images from 60 s (used in thermo-
cycler and microscope measurements) to 30 s (used in smart-
phone measurements).
The y-intercept of the ﬁ t in Figure 4(b) is also signiﬁ cantly 
smaller than those in Figure 2(b) (14.68 min versus 29.1 min 
and 33.3 min), suggesting that the smaller droplet size may 
contribute to a more rapid RT-LAMP reaction, a phenomenon 
that has been discussed elsewhere [28]. This result may be 
leveraged toward achieving the end goal of a rapid viral load 
test.
Lysed whole blood with smartphone imaging. Data from ly-
s ed blood measurements imaged with the smartphone dem-
onstrate two signiﬁ cant steps toward the goals of this paper. 
The replacement of laboratory hardware (e.g., thermocycler 
fluorescence detection or fluorescence microscope) with a 
common smartphone is a core aspect of the novelty of this 
paper. First, this paper demonstrates that the lysed blood RT-
LAMP measurement can be performed with existing mobile 
technology that is at least as affordable as a high-end smart-
phone. Furthermore, trends suggest that mobile communica-
tions technologies will continue to improve in capabilities 
and decrease in cost: an exciting outlook for ﬂ uorescence and 
other optics-based point-of-care diagnostics. Second, our 
platform (consisting of a 3D printed platform, an LED light 
source, an emission filter, and a small form-factor heating 
stage) suggests that, if adequately robust, an add-on compo-
nent may be developed as an attachment to existing smart-
phones, shifting the computation and imaging burden from 
components integrated with the diagnostic platform to a 
consumer item that is becoming ubiquitous, even in resource-
limited settings [29]. This shift could signiﬁ cantly reduce the 
production and deployment costs of such a technology.
4.4 Compatibility with other viral nucleic acids
Anticipating co-infection with other blood-borne viruses may 
be important for practical HIV nucleic acid tests, since the 
incidence of co-infection with HIV and one or more other vi-
ruses is high, particularly in populations of intravenous drug 
users [2, 30]. Most significantly, we have demonstrated that 
hepatitis viral nucleic acids at high concentrations (equivalent 
to approximately 1.6 × 103 of each virus per 60 nL reaction) in 
purified form do not amplify in the RT-LAMP assay that is 
designed for HIV.
A more detailed analysis gives a P of 1.8718E–6 from a 
standard t test, indicating a signiﬁ cant decrease in threshold 
time for the sample containing nucleic acid from all three 
viruses versus the sample containing only RNA from HIV. 
This result indicates a need for more rigorous characteriza-
tion of this phenomenon in future work. One explanation for 
a decreased threshold time is the presence of the hepatitis B 
genome, which is a circular, partially dsDNA, at a relatively 
high concentration (approximately 1600 copies· RXN–1). Its 
presence may produce an effect that is not seen in whole 
blood, since mature erythrocytes do not contain DNA, and 
our simulated co-infected sample would contain a new sig-
nal source from dsDNA intercalating dye. Leukocytes in the 
lysed whole blood sample would be very rare (a few per nL of 
blood), and genomic DNA from these sources may be pack-
aged and largely inaccessible to the dsDNA dye. Because no 
ampliﬁ cation was observed in the HIV-negative, HBV/HCV-
positive samples, we consider it unlikely that HCV RNA or 
HBV DNA is acting as a non-speciﬁ c template for LAMP and 
producing incorrect reaction products.
4.5 Integrated experiments
Our integrated experiments demonstrate the capacity of the 
test for quantitative viral load measurements based on reac-
tion kinetics or digital statistical methods. The slope of the ﬁ t 
to the threshold time plot in Figure 6(c) is comparable to the 
original characterization shown in Figure 2, suggesting that 
the integrated approach has the capacity to be quantitative—
and perhaps can be demonstrated to have greater sensitivity 
upon optimization of reaction chemistry, incubation tem-
perature, and other factors. Bars showing differences that are 
statistically significant between concentrations indicate the 
resolution of the integrated test performed here at a 95% con-
ﬁ dence level.
Clearly, several factors need to be improved and addressed 
in order to move toward a fully automated platform. The 
experiment ﬂ ow described in Figure 6(a) consists of several 
components that are compatible with a point-of-care, micro-
ﬂ uidic cartridge-based in vitro diagnostic platform: the volu-
metric metering of 10 μL of whole blood, microﬂ uidic sample 
processing, nanoliter-sized reaction droplets, a silicon chip 
substrate, and smartphone ﬂ uorescence imaging. The process 
described here does, however, include the manual step of 
transferring lysed blood from the microﬂ uidic module, mix-
ing it with primer-less RT-LAMP master mix, and placing 
droplets onto the chip.
We believe the issues requiring this handling step can be 
addressed by common industry methods not easily demon-
strated in the research lab, such as sample distribution into 
a nanoliter-scale reaction well [31]. The issue of the addition 
of reaction components to the sample could be addressed by 
lyophilization or by freeze-drying reagents that are then re-
hydrated by the sample. Lyophilized LAMP master mixes 
have been described in Refs. [32, 33]. In addition, although 
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air-drying reaction components other than primers were 
problematic on our current platform, we observed that the 
RT-LAMP master mix used here can be lyophilized in a com-
mercial freeze-drier in 0.2 mL reaction tubes (see the Supple-
mentary Information), and that ampliﬁ cation capabilities are 
retained. We did not have the equipment available to attempt 
this process on-chip.
4.6 Quantiﬁ cation by threshold time
The measurements presented here exhibit a trend in thresh-
old time versus virus number that suggests that a kinetic 
measurement based on the time takes an array of droplets to 
react may be a suitable method to quantify viral load, though 
the limits of the resolution are still to be determined in an 
improved platform. For this approach, the sensitivity of the 
reaction, determined by the slope of the ﬁ t to threshold time 
versus virus number, may need to be increased by optimiz-
ing the reaction, including adjustments to enzyme and buffer 
concentrations or to incubation temperature. Additional opti-
mization would need to be performed in order to improve (i.e., 
lower) the lower limit of detection of the reaction.
Although these improvements may be made, a lysed whole 
blood approach will be inherently limited in its capabilities 
by the reaction volume and dilution factor in lysis buffer. 
For this reason, a variation on the approach involving digital 
LAMP may be considered.
4.7 Quantiﬁ cation by digital LAMP
Digital LAMP and PCR approaches have been widely de-
scribed in Refs. [21, 34–39]. The primary advantage of a 
digital approach is that it relies only on an endpoint mea-
surement—whether a reaction of a small volume ampliﬁ es or 
not—from which concentration can be approximated by mea-
suring hundreds, thousands, or millions of droplets. The ap-
proach we describe here could be scaled up for digital LAMP 
by constructing large arrays of droplets with an automated 
distribution method.
The upper and lower limits of viral load detection in a 
digital approach are defined by the number of individual 
reaction droplets and the total volume of the sample tested. 
Since the distribution of viruses in reaction droplets is gov-
erned by Poisson statistics, we have briefly reviewed these 
principles in the Supplementary Information for this paper 
in order to demonstrate the theoretical utility in clinical HIV 
management of a scaled-up platform that tests a ﬁ nger-prick 
droplet of whole blood. For example, a digital LAMP ap-
proach requiring just 9 μL of whole blood would be capable 
of indicating viral loads lower than 500 mL–1 of whole blood, 
with much greater accuracy in the range of 104–106 mL–1 (see 
the Supplementary Information). While this approach can-
not compete with the technical speciﬁ cations of state-of-the-
art systems (lower limit < 10 mL–1), it would be of practical 
value, such as in showing declines in viremia following a 
drug regimen change or in identifying cases of viral rebound 
in settings where the gold standard of care is inaccessible [40]. 
The capacity of this platform as a digital LAMP test increases 
with larger sample sizes and increased number of reaction 
droplets.
5 Conclusions
In performing these experiments and the preparation of this 
manuscript, the challenge of finding a sample-to-answer 
point-of-care HIV viral load quantification solution was 
viewed as two parallel objectives: ① sample processing, 
which traditionally involves isolating or enriching the ana-
lyte from its complex matrix, and ② analyte detection. We 
broadly considered various approaches to sample processing 
that might be integrated with a microchip LAMP approach, 
many of which were guided by the notion that the presence 
of cellular material is not compatible with nucleic acid am-
plification methods. Many of these approaches resulted in 
the dilution of the analyte by a factor of ten or more, while 
our approach results in a dilution by only a factor of five, 
prior to the addition of LAMP reagents with one simple 
and easily implemented processing step that neither puri-
ﬁ es nor enriches. This key merit of our approach can signiﬁ -
cantly reduce the complexity of and cost for a point-of-care 
device.
The measurements presented here demonstrate that an RT-
LAMP quantification approach is indeed compatible with 
minimally processed whole blood. To our knowledge, RT-
LAMP in lysed whole blood has only been employed by one 
group, which performed a non-quantitative measurement 
in a reaction tube on a portable heating device [17]. We dem-
onstrate quantitative detection with the ability to resolve 10-
fold changes in concentration above 6.7E+4 μL–1 and 100-fold 
changes in concentrations above 670 μL–1. We observed 60 nL 
droplets with as few as three viruses per reaction amplify, 
which corresponds to a whole blood virus concentration of 
670 μL–1. We also discussed that the true power of this ap-
proach may be in a quantitative digital LAMP format rather 
than a kinetic measurement. Our implementation of the lysed 
whole blood approach in a microchip format with mobile 
phone imaging represents a signiﬁ cant stride toward a prac-
tical solution to viral load measurements in resource-limited 
settings.
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